Sanofi India Limited (SANOFI.BO)
INR 6090.0
(-0.54%)
INR 6090.0
(-0.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.79 Billion INR | 13.0% |
| 2022 | 6.76 Billion INR | -3.3% |
| 2021 | 6.99 Billion INR | 9.85% |
| 2020 | 6.36 Billion INR | 16.17% |
| 2019 | 5.48 Billion INR | 8.58% |
| 2018 | 5.04 Billion INR | 18.81% |
| 2017 | 4.24 Billion INR | 6.65% |
| 2016 | 3.98 Billion INR | 20.51% |
| 2015 | 3.3 Billion INR | 8.28% |
| 2014 | 3.05 Billion INR | -16.09% |
| 2013 | 3.63 Billion INR | 38.23% |
| 2012 | 2.63 Billion INR | -7.47% |
| 2011 | 2.84 Billion INR | 19.63% |
| 2010 | 2.37 Billion INR | -1.57% |
| 2009 | 2.41 Billion INR | -7.27% |
| 2008 | 2.6 Billion INR | 16.78% |
| 2007 | 2.23 Billion INR | -10.99% |
| 2006 | 2.5 Billion INR | 5.87% |
| 2005 | 2.36 Billion INR | 7.84% |
| 2004 | 2.19 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.06 Billion INR | -48.92% |
| 2024 Q1 | 2.08 Billion INR | 17.89% |
| 2023 Q2 | 1.68 Billion INR | -23.52% |
| 2023 Q1 | 2.2 Billion INR | 40.34% |
| 2023 FY | 7.64 Billion INR | 13.0% |
| 2023 Q4 | 1.77 Billion INR | -10.64% |
| 2023 Q3 | 1.98 Billion INR | 17.76% |
| 2022 FY | 6.76 Billion INR | -3.3% |
| 2022 Q3 | 1.71 Billion INR | 13.95% |
| 2022 Q4 | 1.56 Billion INR | -8.51% |
| 2022 Q1 | 1.83 Billion INR | 57.87% |
| 2022 Q2 | 1.5 Billion INR | -18.03% |
| 2021 Q4 | 1.16 Billion INR | -36.96% |
| 2021 Q1 | 1.69 Billion INR | 2.05% |
| 2021 FY | 6.99 Billion INR | 9.85% |
| 2021 Q2 | 2.26 Billion INR | 33.73% |
| 2021 Q3 | 1.84 Billion INR | -18.36% |
| 2020 FY | 6.36 Billion INR | 16.17% |
| 2020 Q1 | 1.85 Billion INR | 1.15% |
| 2020 Q2 | 1.85 Billion INR | 0.22% |
| 2020 Q3 | 1.86 Billion INR | 0.32% |
| 2020 Q4 | 1.65 Billion INR | -11.21% |
| 2019 FY | 5.48 Billion INR | 8.58% |
| 2019 Q1 | 1.5 Billion INR | 14.6% |
| 2019 Q2 | 1.55 Billion INR | 2.99% |
| 2019 Q3 | 1.72 Billion INR | 10.89% |
| 2019 Q4 | 1.83 Billion INR | 6.57% |
| 2018 Q4 | 1.31 Billion INR | -29.87% |
| 2018 Q1 | 2.69 Billion INR | 112.45% |
| 2018 FY | 5.04 Billion INR | 18.81% |
| 2018 Q2 | 1.59 Billion INR | -40.69% |
| 2018 Q3 | 1.87 Billion INR | 17.26% |
| 2017 Q4 | 1.26 Billion INR | -29.03% |
| 2017 Q3 | 1.78 Billion INR | 51.14% |
| 2017 Q2 | 1.18 Billion INR | 28.45% |
| 2017 Q1 | 921 Million INR | 7.09% |
| 2017 FY | 4.24 Billion INR | 6.65% |
| 2016 Q1 | 1.28 Billion INR | 33.99% |
| 2016 FY | 3.98 Billion INR | 20.51% |
| 2016 Q2 | 1.34 Billion INR | 4.36% |
| 2016 Q4 | 860 Million INR | -35.87% |
| 2016 Q3 | 1.34 Billion INR | 0.0% |
| 2015 Q1 | 764 Million INR | 63.81% |
| 2015 FY | 3.3 Billion INR | 8.28% |
| 2015 Q2 | 1.02 Billion INR | 34.69% |
| 2015 Q3 | 1.22 Billion INR | 18.85% |
| 2015 Q4 | 959 Million INR | -21.59% |
| 2014 Q3 | 940 Million INR | 7.55% |
| 2014 Q4 | 466.4 Million INR | -50.38% |
| 2014 FY | 3.05 Billion INR | -16.09% |
| 2014 Q1 | 785 Million INR | -22.81% |
| 2014 Q2 | 874 Million INR | 11.34% |
| 2013 FY | 3.63 Billion INR | 38.23% |
| 2013 Q1 | 660 Million INR | -0.92% |
| 2013 Q2 | 792 Million INR | 20.0% |
| 2013 Q3 | 1.16 Billion INR | 47.1% |
| 2013 Q4 | 1.01 Billion INR | -12.7% |
| 2012 Q4 | 666.1 Million INR | -12.81% |
| 2012 Q1 | 598 Million INR | 10.74% |
| 2012 FY | 2.63 Billion INR | -7.47% |
| 2012 Q2 | 603 Million INR | 0.84% |
| 2012 Q3 | 764 Million INR | 26.7% |
| 2011 FY | 2.84 Billion INR | 19.63% |
| 2011 Q2 | 735 Million INR | 0.0% |
| 2011 Q3 | 811 Million INR | 10.34% |
| 2011 Q4 | 539.99 Million INR | -33.42% |
| 2010 FY | 2.37 Billion INR | -1.57% |
| 2009 FY | 2.41 Billion INR | -7.27% |
| 2008 FY | 2.6 Billion INR | 16.78% |
| 2007 FY | 2.23 Billion INR | -10.99% |
| 2006 FY | 2.5 Billion INR | 5.87% |
| 2005 FY | 2.36 Billion INR | 7.84% |
| 2004 FY | 2.19 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 43.461% |
| Cipla Limited | 105.7 Billion INR | 92.622% |
| Gland Pharma Limited | 9.9 Billion INR | 21.281% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 42.663% |
| Kopran Limited | 615.26 Million INR | -1167.586% |
| Marksans Pharma Limited | 7.79 Billion INR | -0.095% |
| NGL Fine-Chem Limited | 416.27 Million INR | -1773.539% |
| Pfizer Limited | 9.61 Billion INR | 18.859% |
| SMS Pharmaceuticals Limited | 833.64 Million INR | -835.531% |